{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:05:01Z","timestamp":1790683501178,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40744-026-00872-z","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:01:54Z","timestamp":1784023314000},"page":"1259-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term Comparative Adherence and Switch Rates in Patients Receiving Advanced Therapies for Rheumatoid Arthritis After Use of One TNF Inhibitor"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-7019","authenticated-orcid":false,"given":"Christina","family":"Charles-Schoeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Oelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Zueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Markley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siran","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"872_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070856","volume":"384","author":"P Brown","year":"2024","unstructured":"Brown P, Pratt AG, Hyrich KL. Therapeutic advances in rheumatoid arthritis. BMJ. 2024;384:e070856.","journal-title":"BMJ"},{"issue":"11","key":"872_CR2","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","volume":"38","author":"KJ Johnson","year":"2019","unstructured":"Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol. 2019;38(11):2967\u201376.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"872_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005784","volume":"11","author":"S Ajeganova","year":"2025","unstructured":"Ajeganova S, Forslind K, Hafstr\u00f6m I. The equivocal opposite effects of lower and higher body mass index at diagnosis on radiographic joint damage progression in early rheumatoid arthritis: an inception cohort study over 15 years. RMD Open. 2025;11(3):e005784.","journal-title":"RMD Open"},{"issue":"1","key":"872_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2030-8","volume":"21","author":"PM Ten Klooster","year":"2019","unstructured":"Ten Klooster PM, Versteeg LGA, Oude Voshaar MAH, et al. Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch rheumatoid arthritis monitoring (DREAM) registry. Arthritis Res Ther. 2019;21(1):237.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"872_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"872_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"872_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40744-025-00747-9","volume":"12","author":"R Kanda","year":"2025","unstructured":"Kanda R, Miyazaki Y, Nakayamada S, et al. Effective second-line b\/tsDMARDs for patients with rheumatoid arthritis unresponsive to first-line b\/tsDMARDs from the first registry. Rheumatol Ther. 2025;12(2):353\u201369.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"872_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40744-020-00226-3","volume":"7","author":"MJ Bergman","year":"2020","unstructured":"Bergman MJ, Kivitz AJ, Pappas DA, et al. Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis. Rheumatol Ther. 2020;7(4):775\u201392.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"872_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/acr2.11646","volume":"6","author":"C Edgerton","year":"2024","unstructured":"Edgerton C, Frick A, Helfgott S, et al. Real-world treatment and care patterns in patients with rheumatoid arthritis initiating first-line tumor necrosis factor inhibitor therapy in the United States. ACR Open Rheumatol. 2024;6(4):179\u201388.","journal-title":"ACR Open Rheumatol"},{"issue":"11","key":"872_CR10","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s12325-017-0617-5","volume":"34","author":"B Chastek","year":"2017","unstructured":"Chastek B, Chen CI, Proudfoot C, et al. Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. Adv Ther. 2017;34(11):2422\u201335.","journal-title":"Adv Ther"},{"issue":"10","key":"872_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/acr.24358","volume":"73","author":"AR Karpes Matusevich","year":"2021","unstructured":"Karpes Matusevich AR, Duan Z, Zhao H, et al. Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis: a comparison of cycling versus swapping strategies. Arthritis Care Res (Hoboken). 2021;73(10):1461\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"872_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211002682","volume":"13","author":"A Migliore","year":"2021","unstructured":"Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720x211002682.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"872_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","volume":"20","author":"B Chastek","year":"2017","unstructured":"Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. J Med Econ. 2017;20(5):464\u201373.","journal-title":"J Med Econ"},{"key":"872_CR14","unstructured":"Pharmacy quality alliance adherence measures. https:\/\/www.pqaalliance.org\/adherence-measures. Accessed 26 Feb 2026."},{"issue":"10","key":"872_CR15","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1111\/bcp.15391","volume":"88","author":"LL Dalli","year":"2022","unstructured":"Dalli LL, Kilkenny MF, Arnet I, et al. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool ten-spiders. Br J Clin Pharmacol. 2022;88(10):4427\u201342.","journal-title":"Br J Clin Pharmacol"},{"key":"872_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2147\/PPA.S140457","volume":"11","author":"L Li","year":"2017","unstructured":"Li L, Cui Y, Yin R, et al. Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Patient Prefer Adherence. 2017;11:1343\u201356.","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"872_CR17","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1007\/s12325-023-02619-6","volume":"40","author":"M Bergman","year":"2023","unstructured":"Bergman M, Chen N, Thielen R, Zueger P. One-year medication adherence and persistence in rheumatoid arthritis in clinical practice: a retrospective analysis of upadacitinib, adalimumab, baricitinib, and tofacitinib. Adv Ther. 2023;40(10):4493\u2013503.","journal-title":"Adv Ther"},{"issue":"9","key":"872_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18094872","volume":"18","author":"E Menditto","year":"2021","unstructured":"Menditto E, Cahir C, Malo S, et al. Persistence as a robust indicator of medication adherence-related quality and performance. Int J Environ Res Public Health. 2021;18(9):4872.","journal-title":"Int J Environ Res Public Health"},{"key":"872_CR19","doi-asserted-by":"publisher","first-page":"1456251","DOI":"10.3389\/fmed.2024.1456251","volume":"11","author":"N Aksoy","year":"2024","unstructured":"Aksoy N, Ozturk N, Agh T, Kardas P. Adherence to the antirheumatic drugs: a systematic review and meta-analysis. Front Med (Lausanne). 2024;11:1456251.","journal-title":"Front Med (Lausanne)"},{"key":"872_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.752879","volume":"12","author":"N Carballo","year":"2021","unstructured":"Carballo N, Garcia-Alz\u00f3rriz E, Ferr\u00e1ndez O, et al. Impact of non-persistence on healthcare resource utilization and costs in patients with immune-mediated rheumatic diseases initiating subcutaneous TNF-alpha inhibitors: a before-and-after study. Front Pharmacol. 2021;12:752879.","journal-title":"Front Pharmacol"},{"key":"872_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221091450","volume":"14","author":"DJ Park","year":"2022","unstructured":"Park DJ, Choi SE, Kang JH, et al. Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure. Ther Adv Musculoskelet Dis. 2022;14:1759720x221091450.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"872_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211060910","volume":"13","author":"P Bogas","year":"2021","unstructured":"Bogas P, Plasencia-Rodriguez C, Navarro-Comp\u00e1n V, et al. Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study. Ther Adv Musculoskelet Dis. 2021;13:1759720x211060910.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"872_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/RHU.0000000000002013","volume":"29","author":"L Bessette","year":"2023","unstructured":"Bessette L, Movahedi M, Reed G, et al. Does the type of failure and the choice of the second biologic influence response and persistence on medication in rheumatoid arthritis? J Clin Rheumatol. 2023;29(7):332\u201340.","journal-title":"JCR J Clin Rheumatol"},{"issue":"1","key":"872_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40744-024-00736-4","volume":"12","author":"P Youssef","year":"2025","unstructured":"Youssef P, Ciciriello S, Tahir T, et al. Real-world persistence and effectiveness of upadacitinib versus other janus kinase inhibitors and tumor necrosis factor inhibitors in Australian patients with rheumatoid arthritis. Rheumatol Ther. 2025;12(1):173\u2013202.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"872_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072300","volume":"14","author":"BTP Gilbert","year":"2024","unstructured":"Gilbert BTP, Mongin D, Aymon R, et al. Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA. BMJ Open. 2024;14(3):e072300.","journal-title":"BMJ Open"},{"issue":"9","key":"872_CR26","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s12325-024-02948-0","volume":"41","author":"R Caporali","year":"2024","unstructured":"Caporali R, Kadakia A, Howell O, et al. A real-world comparison of clinical effectiveness in patients with rheumatoid arthritis treated with upadacitinib, tumor necrosis factor inhibitors, and other advanced therapies after switching from an initial tumor necrosis factor inhibitor. Adv Ther. 2024;41(9):3706\u201321.","journal-title":"Adv Ther"},{"key":"872_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.03.013","author":"E Mysler","year":"2026","unstructured":"Mysler E, Sidiropoulos PI, Balanescu A, et al. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study. Ann Rheum Dis. 2026. https:\/\/doi.org\/10.1016\/j.ard.2026.03.013.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00872-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00872-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00872-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:28:48Z","timestamp":1790681328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00872-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00872-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christina Charles-Schoeman has received consultancy fees from AbbVie, BMS, Boehringer Ingelheim, Octapharma, Pfizer, Recludix and Sana Biotechnology; and grant\/research support from AbbVie, Alexion, BMS, CSL Behring, Janssen, Octapharma, Pfizer and Priovant. Kurt Oelke has been a member of the speakers\u2019 bureau for AbbVie, Amgen, Bristol Myers Squibb, Crescendo Biosciences, GSK, Pfizer Inc, and UCB. Patrick M Zueger, Yi Peng, Gregory Markley, Richard Thielen, and Siran Fang are employees of AbbVie and hold shares and\/or stock options in the company. Martin Bergman is a shareholder of Johnson and Johnson (parent company of Janssen).","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors had a data license contract that granted them permission to access and conduct analyses using data from the Merative MarketScan\n                      \u00ae\n                      Research Databases and publish the results. This was a retrospective database analysis that did not collect, use, or transmit patient-identifiable data, so informed consent was not needed. Ethics committee or Institutional Review Board approval was not needed. This study was compliant with data security requirements of the Health Insurance Portability and Accountability Act of 1996.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}